These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 28930171)

  • 21. Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer.
    Ogishima T; Shiina H; Breault JE; Tabatabai L; Bassett WW; Enokida H; Li LC; Kawakami T; Urakami S; Ribeiro-Filho LA; Terashima M; Fujime M; Igawa M; Dahiya R
    Clin Cancer Res; 2005 Feb; 11(3):1028-36. PubMed ID: 15709168
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel combined miRNA and methylation marker panel (miMe) for prediction of prostate cancer outcome after radical prostatectomy.
    Strand SH; Bavafaye-Haghighi E; Kristensen H; Rasmussen AK; Hoyer S; Borre M; Mouritzen P; Besenbacher S; Orntoft TF; Sorensen KD
    Int J Cancer; 2019 Dec; 145(12):3445-3452. PubMed ID: 31125115
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overexpression of high mobility group box 1 with poor prognosis in patients after radical prostatectomy.
    Li T; Gui Y; Yuan T; Liao G; Bian C; Jiang Q; Huang S; Liu B; Wu D
    BJU Int; 2012 Dec; 110(11 Pt C):E1125-30. PubMed ID: 22672360
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined loss of TFF3 and PTEN is associated with lethal outcome and overall survival in men with prostate cancer.
    Abou-Ouf H; Ghosh S; Box A; Palanisamy N; Bismar TA
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1751-1759. PubMed ID: 31129769
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical significance of miRNA host gene promoter methylation in prostate cancer.
    Daniunaite K; Dubikaityte M; Gibas P; Bakavicius A; Rimantas Lazutka J; Ulys A; Jankevicius F; Jarmalaite S
    Hum Mol Genet; 2017 Jul; 26(13):2451-2461. PubMed ID: 28398479
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Random forest-based modelling to detect biomarkers for prostate cancer progression.
    Toth R; Schiffmann H; Hube-Magg C; Büscheck F; Höflmayer D; Weidemann S; Lebok P; Fraune C; Minner S; Schlomm T; Sauter G; Plass C; Assenov Y; Simon R; Meiners J; Gerhäuser C
    Clin Epigenetics; 2019 Oct; 11(1):148. PubMed ID: 31640781
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aberrant Promoter Methylation of Protocadherin8 (PCDH8) in Serum is a Potential Prognostic Marker for Low Gleason Score Prostate Cancer.
    Lin YL; Li YL; Ma JG
    Med Sci Monit; 2017 Oct; 23():4895-4900. PubMed ID: 29026066
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Holmes EE; Goltz D; Sailer V; Jung M; Meller S; Uhl B; Dietrich J; Röhler M; Ellinger J; Kristiansen G; Dietrich D
    Clin Epigenetics; 2016; 8():104. PubMed ID: 27708722
    [TBL] [Abstract][Full Text] [Related]  

  • 29. V-ets erythroblastosis virus E26 oncogene homolog (avian)/Trefoil factor 3/high-molecular-weight cytokeratin triple immunostain: a novel tissue-based biomarker in prostate cancer with potential clinical application.
    Park K; Chiu YL; Rubin MA; Demichelis F; Mosquera JM
    Hum Pathol; 2013 Oct; 44(10):2282-92. PubMed ID: 23856515
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aberrant
    Bjerre MT; Strand SH; Nørgaard M; Kristensen H; Rasmussen AK; Mortensen MM; Fredsøe J; Mouritzen P; Ulhøi B; Ørntoft T; Borre M; Sørensen KD
    Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30866497
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy.
    Geybels MS; Wright JL; Bibikova M; Klotzle B; Fan JB; Zhao S; Feng Z; Ostrander EA; Lin DW; Nelson PS; Stanford JL
    Clin Epigenetics; 2016; 8():97. PubMed ID: 27651837
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High RNA-binding motif protein 3 expression is an independent prognostic marker in operated prostate cancer and tightly linked to ERG activation and PTEN deletions.
    Grupp K; Wilking J; Prien K; Hube-Magg C; Sirma H; Simon R; Steurer S; Budäus L; Haese A; Izbicki J; Sauter G; Minner S; Schlomm T; Tsourlakis MC
    Eur J Cancer; 2014 Mar; 50(4):852-61. PubMed ID: 24380696
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Frequent trefoil factor 3 (TFF3) overexpression and promoter hypomethylation in mouse and human hepatocellular carcinomas.
    Okada H; Kimura MT; Tan D; Fujiwara K; Igarashi J; Makuuchi M; Hui AM; Tsurumaru M; Nagase H
    Int J Oncol; 2005 Feb; 26(2):369-77. PubMed ID: 15645121
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy.
    Giesing M; Suchy B; Driesel G; Molitor D
    BJU Int; 2010 Apr; 105(7):1000-10. PubMed ID: 19818074
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impairment of IGF2 gene expression in prostate cancer is triggered by epigenetic dysregulation of IGF2-DMR0 and its interaction with KLF4.
    Schagdarsurengin U; Lammert A; Schunk N; Sheridan D; Gattenloehner S; Steger K; Wagenlehner F; Dansranjavin T
    Cell Commun Signal; 2017 Oct; 15(1):40. PubMed ID: 29017567
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multigene methylation analysis for detection and staging of prostate cancer.
    Enokida H; Shiina H; Urakami S; Igawa M; Ogishima T; Li LC; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
    Clin Cancer Res; 2005 Sep; 11(18):6582-8. PubMed ID: 16166436
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MiR-193b promoter methylation accurately detects prostate cancer in urine sediments and miR-34b/c or miR-129-2 promoter methylation define subsets of clinically aggressive tumors.
    Torres-Ferreira J; Ramalho-Carvalho J; Gomez A; Menezes FD; Freitas R; Oliveira J; Antunes L; Bento MJ; Esteller M; Henrique R; Jerónimo C
    Mol Cancer; 2017 Jan; 16(1):26. PubMed ID: 28143614
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A five-microRNA model (pCaP) for predicting prostate cancer aggressiveness using cell-free urine.
    Fredsøe J; Rasmussen AKI; Mouritzen P; Borre M; Ørntoft T; Sørensen KD
    Int J Cancer; 2019 Nov; 145(9):2558-2567. PubMed ID: 30903800
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Study of genetic and epigenetic alterations in urine samples as diagnostic markers for prostate cancer.
    Dimitriadis E; Kalogeropoulos T; Velaeti S; Sotiriou S; Vassiliou E; Fasoulis L; Klapsas V; Synesiou M; Apostolaki A; Trangas T; Pandis N
    Anticancer Res; 2013 Jan; 33(1):191-7. PubMed ID: 23267145
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation of ERG expression and DNA methylation biomarkers with adverse clinicopathologic features of prostate cancer.
    Kron K; Liu L; Trudel D; Pethe V; Trachtenberg J; Fleshner N; Bapat B; van der Kwast T
    Clin Cancer Res; 2012 May; 18(10):2896-904. PubMed ID: 22452941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.